Linked Life Data

9028939

Source:http://linkedlifedata.com/resource/pubmed/id/9028939

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9028939rdf:typepubmed:Citationlld:pubmed
pubmed-article:9028939lifeskim:mentionsumls-concept:C0018951lld:lifeskim
pubmed-article:9028939lifeskim:mentionsumls-concept:C0002874lld:lifeskim
pubmed-article:9028939lifeskim:mentionsumls-concept:C0024790lld:lifeskim
pubmed-article:9028939lifeskim:mentionsumls-concept:C1522642lld:lifeskim
pubmed-article:9028939lifeskim:mentionsumls-concept:C0221099lld:lifeskim
pubmed-article:9028939lifeskim:mentionsumls-concept:C0334094lld:lifeskim
pubmed-article:9028939lifeskim:mentionsumls-concept:C0332281lld:lifeskim
pubmed-article:9028939lifeskim:mentionsumls-concept:C1457869lld:lifeskim
pubmed-article:9028939pubmed:issue4lld:pubmed
pubmed-article:9028939pubmed:dateCreated1997-3-17lld:pubmed
pubmed-article:9028939pubmed:abstractTextParoxysmal nocturnal hemoglobinuria (PNH) results from somatic mutations in the PIG-A gene, leading to poor presentation of glycosylphosphatidylinositol (GPI)-anchored surface proteins. PNH frequently occurs in association with suppressed hematopoiesis, including frank aplastic anemia (AA). The relationship between GPI-anchored protein expression and bone marrow (BM) failure is unknown. To assess the hematopoietic defect in PNH, the numbers of CD34+ cells, committed progenitors (primary colony-forming cells [CFCs]), and long-term culture-initiating cells (LTC-ICs; a stem cell surrogate) were measured in BM and peripheral blood (PB) of patients with PNH/AA syndrome or patients with predominantly hemolytic PNH. LTC-IC numbers were extrapolated from secondary CFC numbers after 5 weeks of culture, and clonogenicity of LTC-ICs was determined by limiting dilution assays. When compared with normal volunteers (n = 13), PNH patients (n = 14) showed a 4.7-fold decrease in CD34+ cells and an 8.2-fold decrease in CFCs. LTC-ICs in BM and in PB were decreased 7.3-fold and 50-fold, respectively. Purified CD34+ cells from PNH patients had markedly lower clonogenicity in both primary colony cultures and in the LTC-IC assays. As expected, GPI-anchored proteins were decreased on PB cells of PNH patients. On average, 23% of monocytes were deficient in CD14, and 47% of granulocytes and 58% of platelets lacked CD16 and CD55, respectively. In PNH BM, 27% of CD34+ cells showed abnormal GPI-anchored protein expression when assessed by CD59 expression. To directly measure the colony-forming ability of GPI-anchored protein-deficient CD34+ cells, we separated CD34+ cells from PNH patients for the GPI+ and GPI-phenotype; CD59 expression was chosen as a marker of the PNH phenotype based on high and homogeneous expression on fluorescent staining. CD34+ CD59+ and CD34+ CD59-cells from PNH/AA patients showed similarly impaired primary and secondary clonogeneic efficiency. The progeny derived from CD34+ CD59- cells were both CD59- and CD55-. A very small population of CD34+ CD59- cells was also detected in some normal volunteers; after sorting, these CD34+ CD59- cells formed normal numbers of colonies, but their progeny showed lower CD59 levels. Our results are consistent with the existence of PIG-A-deficient clones in some normal individuals. In PNH/AA, progenitor and stem cells are decreased in number and function, but the proliferation in vitro is affected similarly in GPI-protein-deficient clones and in phenotypically normal cells. As measured in the in vitro assays, expansion of PIG-A- clones appears not be caused by an intrinsic growth advantage of cells with the PNH phenotype.lld:pubmed
pubmed-article:9028939pubmed:languageenglld:pubmed
pubmed-article:9028939pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9028939pubmed:citationSubsetAIMlld:pubmed
pubmed-article:9028939pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9028939pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9028939pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9028939pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9028939pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9028939pubmed:statusMEDLINElld:pubmed
pubmed-article:9028939pubmed:monthFeblld:pubmed
pubmed-article:9028939pubmed:issn0006-4971lld:pubmed
pubmed-article:9028939pubmed:authorpubmed-author:SatoTTlld:pubmed
pubmed-article:9028939pubmed:authorpubmed-author:AndersonSSlld:pubmed
pubmed-article:9028939pubmed:authorpubmed-author:YoungN SNSlld:pubmed
pubmed-article:9028939pubmed:authorpubmed-author:SloandE MEMlld:pubmed
pubmed-article:9028939pubmed:authorpubmed-author:MaciejewskiJ...lld:pubmed
pubmed-article:9028939pubmed:issnTypePrintlld:pubmed
pubmed-article:9028939pubmed:day15lld:pubmed
pubmed-article:9028939pubmed:volume89lld:pubmed
pubmed-article:9028939pubmed:ownerNLMlld:pubmed
pubmed-article:9028939pubmed:authorsCompleteYlld:pubmed
pubmed-article:9028939pubmed:pagination1173-81lld:pubmed
pubmed-article:9028939pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:9028939pubmed:meshHeadingpubmed-meshheading:9028939-...lld:pubmed
pubmed-article:9028939pubmed:meshHeadingpubmed-meshheading:9028939-...lld:pubmed
pubmed-article:9028939pubmed:meshHeadingpubmed-meshheading:9028939-...lld:pubmed
pubmed-article:9028939pubmed:meshHeadingpubmed-meshheading:9028939-...lld:pubmed
pubmed-article:9028939pubmed:meshHeadingpubmed-meshheading:9028939-...lld:pubmed
pubmed-article:9028939pubmed:meshHeadingpubmed-meshheading:9028939-...lld:pubmed
pubmed-article:9028939pubmed:meshHeadingpubmed-meshheading:9028939-...lld:pubmed
pubmed-article:9028939pubmed:meshHeadingpubmed-meshheading:9028939-...lld:pubmed
pubmed-article:9028939pubmed:meshHeadingpubmed-meshheading:9028939-...lld:pubmed
pubmed-article:9028939pubmed:meshHeadingpubmed-meshheading:9028939-...lld:pubmed
pubmed-article:9028939pubmed:meshHeadingpubmed-meshheading:9028939-...lld:pubmed
pubmed-article:9028939pubmed:meshHeadingpubmed-meshheading:9028939-...lld:pubmed
pubmed-article:9028939pubmed:meshHeadingpubmed-meshheading:9028939-...lld:pubmed
pubmed-article:9028939pubmed:meshHeadingpubmed-meshheading:9028939-...lld:pubmed
pubmed-article:9028939pubmed:meshHeadingpubmed-meshheading:9028939-...lld:pubmed
pubmed-article:9028939pubmed:meshHeadingpubmed-meshheading:9028939-...lld:pubmed
pubmed-article:9028939pubmed:meshHeadingpubmed-meshheading:9028939-...lld:pubmed
pubmed-article:9028939pubmed:meshHeadingpubmed-meshheading:9028939-...lld:pubmed
pubmed-article:9028939pubmed:meshHeadingpubmed-meshheading:9028939-...lld:pubmed
pubmed-article:9028939pubmed:year1997lld:pubmed
pubmed-article:9028939pubmed:articleTitleImpaired hematopoiesis in paroxysmal nocturnal hemoglobinuria/aplastic anemia is not associated with a selective proliferative defect in the glycosylphosphatidylinositol-anchored protein-deficient clone.lld:pubmed
pubmed-article:9028939pubmed:affiliationHematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.lld:pubmed
pubmed-article:9028939pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9028939lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9028939lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9028939lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9028939lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9028939lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9028939lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9028939lld:pubmed